Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Honing Treatment Strategies in Advanced Prostate Cancer: Latest Evidence to Guide Clinical Practice
  • CME
  • CE

Credits Available
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Registered Nurses: 1.0 Nursing contact hour
Pharmacists: 1.0 contact hour (0.1 CEUs)
Released: December 18, 2020 Expiration: December 17, 2021
Start Activity
Provided by USF Health in partnership with Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bayer HealthCare Pharmaceuticals Inc.
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Sanofi Genzyme Corporation
Robert Dreicer, MD, MS, MACP, FASCO
Charles J. Ryan, MD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Plan optimal, individualized therapeutic strategies for patients with advanced or metastatic prostate cancer through exposure to expert insights and recommendations, real-world experience, and evidence-based and consensus-based guidelines
  • Evaluate new therapeutic options for nonmetastatic castration-resistant prostate cancer
  • Compare combinations of ADT with various agents vs ADT alone for metastatic hormone-sensitive prostate cancer
  • Apply expert recommendations for the sequencing of available and emerging hormonal, cytotoxic, immunologic, bone-directed, molecularly targeted, and other novel therapies (alone and in combination) to safely and effectively integrate them into the care of patients with metastatic castration-resistant prostate cancer
  • Assess and manage the risk for cardiotoxicity or bone loss prior to and/or during prostate cancer treatment
  • Refer appropriate patients with prostate cancer to ongoing clinical trials assessing novel therapies alone and in combination throughout the disease continuum to aid in trial enrollment

Information on this Educational Activity

Faculty

Charles J. Ryan, MD

Professor of Medicine
B.J. Kennedy Chair in Clinical Medical Oncology
Director,
 Division of Hematology, Oncology and Transplantation
Department of Medicine
University of Minnesota
Oncologist
Division of Hematology, Oncology and Transplantation
University of Minnesota Health Clinics and Surgery Center
Minneapolis, Minnesota

Charles J. Ryan, MD has disclosed that he serves on advisory boards for AAA, Bayer, Clovis, Myovant, and Roivant; he has research support from Clovis and Sanofi/Genzyme.
Robert Dreicer, MD, MS, MACP, FASCO

Section Head, Medical Oncology
Associate Director for Clinical Research
Deputy Director
University of Virginia Cancer Center
Co-Director, Paul Mellon Urologic Institute
Professor of Medicine and Urology
University of Virginia School of Medicine
Charlottesville,Virginia

Robert Dreicer, MD, MS, MACP, FASCO has disclosed that he serves on advisory boards for Astellas, Bayer, Eisai, EMD Serono, Genentech, Myovant, Novartis, Pfizer, and Seattle Genetics.

Staff

Marie N. Becker, PhD

Scientific Director

Marie N. Becker, PhD, has no relevant conflicts of interest to report.
Elizabeth O’Connell, PhD
Elizabeth O’Connell, PhD has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD has no relevant conflicts of interest to report.
Jason Everly, PharmD

Director, Program Development and Educational Impact

Jason Everly, PharmD, has no relevant conflicts of interest to report.
Krista Marcello

Associate Director, Educational Strategy

Krista Marcello, has no relevant conflicts of interest to report.
Kristi Kay Orbaugh, RN, MSN, RNP, AOCN

Adult Oncology Nurse Practitioner
Community Hospital Oncology Physicians
Indianapolis, Indiana

Kristi Orbaugh, MSN, RNP, AOCN, has no relevant conflicts of interest to report.

USF Health OCPD staff have no relevant conflicts of interest to report.

Target Audience

This program is intended for physicians, nurses, clinical pharmacists, and other healthcare providers who care for patients with advanced prostate cancer.

Goal

The goal of this activity is to improve participants’ knowledge of, confidence in, and competence in integrating recent findings into the treatment of patients with prostate cancer.

USF Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

Physician Continuing Medical Education

Credit Designation

USF Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

USF Health is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

A maximum of 1.0 contact hour may be earned by learners who successfully complete this nursing continuing professional development activity.

Pharmacist Continuing Education

USF Health is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This knowledge-based program has been approved for 1.0 contact hour (0.1 CEU). Universal program number is as follows: 0230-9999-20-021-H01-P

Type of activity: Knowledge

For Pharmacists:
It is the responsibility of the pharmacy participant to ensure the provider has the learner’s birthday and e-Profile ID (ePID)/NABP number; it is the responsibility of the provider to submit to CPE Monitor participant information within 60 days of the activity for all participants who have attended, attested to their participation, and provided their ePID/NABP number and birthdate.

ACPE indicates it is the responsibility of the pharmacy professional to confirm the status of their NABP contact hours before 60 days past the activity. If there are any discrepancies, contact the provider immediately. You may contact USF Health through cpdsupport@usf.edu.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 18, 2020, through December 17, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Current Recommendations for Metastatic Hormone-Sensitive Prostate Cancer
  • CME
  • CE

Loading...
Join a prostate cancer expert as he discusses the current recommendations for optimal management of metastatic HSPC with a focus on ADT combination therapies
Robert Dreicer, MD, MS, MACP, FASCO
Charles J. Ryan, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Registered Nurses: 1.0 Nursing contact hour
Pharmacists: 1.0 contact hour (0.1 CEUs)
Released: December 18, 2020 Expiration: December 17, 2021
PreviousNext

Related Content

Focused slideset from experts on the use of radium-223 and PSMA lutetium in the treatment of metastatic castration-resistant prostate cancer, from Clinical Care Options (CCO)

Chris Parker, MD Bertrand Tombal, MD, PhD Released: July 20, 2021

On-demand webcast on PARP inhibitor combination therapies in prostate cancer featuring 3 faculty experts presented by Clinical Care Options (CCO)

Charles J. Ryan, MD
Program Director
person default Wassim Abida, MD, PhD Joaquin Mateo, MD, PhD
Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: July 7, 2021 Expired: July 6, 2022

Dr. Charles J. Ryan discusses the rationale and evidence for PARP inhibitor combinations in prostate cancer, from Clinical Care Options (CCO)

Charles J. Ryan, MD Released: July 2, 2021

Downloadable PDF with highlights from a CCO podcast on PARP inhibitors and emerging combination strategies in prostate cancer.

Charles J. Ryan, MD
Program Director
person default Wassim Abida, MD, PhD Joaquin Mateo, MD, PhD
Released: June 30, 2021

Video Chapters


Provided by USF Health in partnership with Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bayer HealthCare Pharmaceuticals Inc.
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Sanofi Genzyme Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue